- Home
- CNSP vs CHEK Comparison
CNSP vs CHEK Comparison
Compare CNSP & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- CHEK
- Stock Information
- Founded
- CNSP 2017
- CHEK 2004
- Country
- CNSP United States
- CHEK Israel
- Employees
- CNSP N/A
- CHEK N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- CHEK Medical Electronics
- Sector
- CNSP Health Care
- CHEK Health Care
- Exchange
- CNSP Nasdaq
- CHEK Nasdaq
- Market Cap
- CNSP 5.6M
- CHEK 4.5M
- IPO Year
- CNSP 2019
- CHEK 2015
- Fundamental
- Price
- CNSP $1.25
- CHEK $0.81
- Analyst Decision
- CNSP Hold
- CHEK
- Analyst Count
- CNSP 1
- CHEK 0
- Target Price
- CNSP N/A
- CHEK N/A
- AVG Volume (30 Days)
- CNSP 332.7K
- CHEK 52.9K
- Earning Date
- CNSP 05-14-2025
- CHEK 05-14-2025
- Dividend Yield
- CNSP N/A
- CHEK N/A
- EPS Growth
- CNSP N/A
- CHEK N/A
- EPS
- CNSP N/A
- CHEK N/A
- Revenue
- CNSP N/A
- CHEK N/A
- Revenue This Year
- CNSP N/A
- CHEK N/A
- Revenue Next Year
- CNSP N/A
- CHEK N/A
- P/E Ratio
- CNSP N/A
- CHEK N/A
- Revenue Growth
- CNSP N/A
- CHEK N/A
- 52 Week Low
- CNSP $1.21
- CHEK $0.56
- 52 Week High
- CNSP $800.00
- CHEK $3.04
- Technical
- Relative Strength Index (RSI)
- CNSP 30.28
- CHEK 47.11
- Support Level
- CNSP $1.28
- CHEK $0.77
- Resistance Level
- CNSP $1.46
- CHEK $0.86
- Average True Range (ATR)
- CNSP 0.38
- CHEK 0.08
- MACD
- CNSP -0.12
- CHEK 0.00
- Stochastic Oscillator
- CNSP 1.18
- CHEK 41.46
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.